William Blair Has Positive Outlook for argenex Q1 Earnings

argenex SE (NASDAQ:ARGX) – Stock analysts at William Blair lifted their Q1 2026 earnings estimates for argenex in a research report issued to clients and investors on Wednesday, September 17th. William Blair analyst M. Minter now anticipates that the company will earn $6.46 per share for the quarter, up from their prior estimate of $4.77. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. William Blair also issued estimates for argenex’s Q2 2026 earnings at $7.20 EPS, Q3 2026 earnings at $8.70 EPS and Q4 2026 earnings at $9.53 EPS.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%.

Other analysts have also recently issued reports about the stock. HC Wainwright increased their price target on shares of argenex from $720.00 to $774.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research note on Sunday, September 14th. Guggenheim reissued a “buy” rating and set a $1,070.00 price target on shares of argenex in a research note on Thursday. Jefferies Financial Group set a $818.00 price target on shares of argenex and gave the company a “buy” rating in a research note on Tuesday, August 26th. Finally, Bank of America increased their price objective on shares of argenex from $880.00 to $887.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $789.20.

argenex Trading Up 0.7%

Shares of argenex stock opened at $736.76 on Friday. The stock has a market capitalization of $45.09 billion, a price-to-earnings ratio of 37.78, a P/E/G ratio of 0.80 and a beta of 0.41. argenex has a 1-year low of $510.05 and a 1-year high of $779.03. The firm’s 50-day moving average price is $668.71 and its two-hundred day moving average price is $611.12.

Institutional Investors Weigh In On argenex

A number of institutional investors have recently modified their holdings of the company. Valeo Financial Advisors LLC boosted its stake in shares of argenex by 203.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,303 shares of the company’s stock valued at $718,000 after purchasing an additional 874 shares during the last quarter. Orion Porfolio Solutions LLC lifted its position in shares of argenex by 17.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,294 shares of the company’s stock valued at $5,674,000 after acquiring an additional 1,558 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of argenex by 6.9% during the 2nd quarter. Thrivent Financial for Lutherans now owns 527 shares of the company’s stock valued at $295,000 after acquiring an additional 34 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of argenex during the 2nd quarter valued at $37,441,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of argenex by 257.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,339 shares of the company’s stock valued at $10,660,000 after acquiring an additional 13,935 shares during the period. 60.32% of the stock is owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.